Recent recommendations from the Alzheimer’s Association (AA) establish amyloid-PET as the gold standard for identifying brain amyloidosis (A) in vivo, and tau PET for quantifying and staging tauopathy (T2). The gene discussed is MAPT; the disease is tauopathy.